Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report

Haemophilia. 2021 Jul;27(4):e495-e497. doi: 10.1111/hae.14209. Epub 2020 Nov 20.

Authors

Maria Giuseppina Cefalo^{1

2}, Francesca Ronco^{1

2}, Giovina Di Felice^{1

2}, Martina Rinelli^{1

2}, Vincenzo Oriana^{1

2}, Michela Massoud^{1

2}, Pietro Merli^{1

2}, Matteo Luciani^{1

2}

Affiliations

¹ Bambino Gesù Pediatric Hospital, Roma, Italy.
² Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.

PMID: 33216432
DOI: 10.1111/hae.14209

No abstract available

Keywords: bleeding disorders; childhood; emicizumab; factor VIII deficiency; inhibitors; von Willebrand disease.

Publication types

Letter

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized
Child
Factor VIII
Humans
von Willebrand Diseases* / complications
von Willebrand Diseases* / drug therapy
von Willebrand Factor

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
von Willebrand Factor
emicizumab
Factor VIII